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Abstract
Curative resection is the only treatment for biliary tract cancer 
that achieves long-term survival. However, patients with 
advanced biliary tract cancer have only a limited prognosis 
even after radical surgical resection. Thus, to improve the long-
term results, the early detection of biliary tract cancer and 
subsequent cure seem to be essential. The purpose of this 
study was to review the literature concerning the risk factors 
for cancerous and precancerous lesions of the biliary tract, and 
prophylactic surgery for these factors. It has been reported 
that pancreaticobiliary maljunction (PBM) with bile duct dila-
tation is a risk factor for gallbladder cancer and bile duct 
cancer, while PBM without bile duct dilatation is a risk factor 
for gallbladder cancer. Thus, in the former group, a prophylac-
tic excision of the common bile duct and gallbladder should 
be recommended, while in the later group, a prophylactic cho-
lecystectomy without bile duct resection may be the appropri-
ate surgical procedure. It has also been reported that primary 
sclerosing cholangitis (PSC) is a risk factor for cholangiocar-
cinoma. Patients with PSC often develop advanced cholangio-
carcinoma with a poor prognosis. In patients with PSC, 
therefore, strict follow-up should be recommended. Adenoma 
and dysplasia have been regarded as precancerous lesions of 
gallbladder cancer. A polypoid lesion of the gallbladder that 
is sessile, has a diameter greater than 10  mm, and /or grows 
rapidly, is highly likely to be cancerous and should be resected. 
Although gallstones seem to be closely associated with gall-
bladder cancer, there is no evidence of a direct causal relation-
ship between gallstones and gallbladder cancer. Thus, a 
cholecystectomy is not advised for asymptomatic cholecysto-
lithiasis. Controversy remains as to whether adenomyomatosis 
of the gallbladder and porcelain gallbladder are associated 
with gallbladder cancer. With respect to ampullary carcinoma, 
adenoma of the ampulla is considered to be a precancerous 
lesion. This article discusses the risk factors for cancerous and 
precancerous lesions of the biliary tract and prophylactic 
treatment for these factors.
Key words Biliary tract neoplasms · Risk factors · Prophylaxis 
therapy · Gallstones · Pancreaticobiliary maljunction · Precan-
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Introduction
One of the possible causes of biliary tract cancer may 
be chronic and continuous stimulation of the biliary 
tract, and cholangitis due to gallstones and the reﬂ  ux of 
pancreatic juice into the biliary tract.
1,2 The underlying 
diseases that potentially cause such a condition include 
pancreaticobiliary maljunction (PBM),
3  primary 
sclerosing cholangitis (PSC),
4–7  chronic cholecystitis,
1 
gallstones,
1,8 and adenomyomatosis.
9 In such patients, 
chronic inﬂ  ammation potentially causes pathological 
changes of the biliary epithelium resulting in precursors 
of biliary tract cancer.
1
Although curative resection is the only treatment for 
biliary tract cancer that achieves long-term survival, 
patients with advanced cancer have only a limited prog-
nosis even after radical surgical resection. To improve 
the long-term results, therefore, the early detection of 
precancerous and cancerous lesions, and subsequent 
cure seem to be essential.
In this article, we discuss the predisposing factors for 
bile duct cancer, gallbladder cancer, and ampullary car-
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cinoma, using a format of clinical questions (CQs) and 
responses. In the responses to the CQs, recommenda-
tions for treatment are noted (grades of these recom-
mendations are deﬁ  ned in Table 1
10). Also, levels of 
evidence are given (in parentheses) for ﬁ  ndings in refer-
ence citations (see deﬁ  nitions of levels in Table 2
10).
Risk factors for bile duct cancer
Pancreaticobiliary maljunction (see CQ 2)
A retrospective nationwide survey (1990 to 1999) of 
PBM in Japan revealed that 10.6% of PBM patients with 
bile duct dilatation were complicated by biliary tract 
cancer, and 33.6% of these biliary tract cancers were bile 
duct cancer
3 (level IV). PBM with bile duct dilatation is 
considered as a risk factor for bile duct cancer.
Primary sclerosing cholangitis (PSC)
Patients wit PSC carry an increased risk of bile duct 
cancer. Five percent to 10% of PSC patients develop 
bile duct cancer
4–7 (level V). Bile duct cancer associated 
with PSC is often advanced with a poor prognosis. PSC, 
therefore, should be recognized as a risk factor for bile 
duct cancer.
Controversy remains as to whether bile duct cancer 
is related to chronic inﬂ  ammation due to gallstones or 
some gene mutations
8,11,12 (level IV).
Risk factors for gallbladder cancer
Pancreaticobiliary maljunction (see CQ 2)
There have been many studies that reported PBM as a 
risk factor for gallbladder cancer. A nationwide survey 
(1990 to 1999) of PBM revealed that the prevalence rate 
of biliary tract cancer was 10.6% in the group with bile 
duct dilatation, while the prevalence rate was 37.9% in 
the group without bile duct dilatation
3 (level IV). With 
respect to the PBM patients who developed biliary tract 
cancer, the incidence of gallbladder cancer was 64.9% 
in those with PBM with bile duct dilatation, whereas the 
incidence was 93.2% in those with PBM without bile 
duct dilatation. Therefore, PBM is an evident risk factor 
for gallbladder cancer. Of note, the frequency of gall-
stones in patients with PBM associated with gallbladder 
cancer is low.
13
Gallstones and porcelain gallbladder (see CQ 3)
It has been well established that gallstones are closely 
associated with gallbladder cancer
1,8  (level V). It has 
also been reported that a stone size of more than 3 cm, 
CQ 1 What are the risk factors for biliary tract and 
ampullary carcinomas?
Pancreaticobiliary maljunction (PBM) with bile duct 
dilatation and primary sclerosing cholangitis (PSC) 
are risk factors for biliary tract cancer (see side 
memos 1 and 2). PBM, particularly that without bile 
duct dilatation, is a risk factor for gallbladder 
cancer.
There are no evident risk factors for ampullary 
carcinoma.
The prevalence rate of biliary tract cancer varies in dif-
ferent geographical regions. Chile and Japan have the 
highest rate in the world, followed by East Asia and 
India (level V).
1,2 Also, there are age differences in the 
incidence of biliary tract cancer.
1 It has been reported 
that the risk factors for biliary tract cancer are, possibly, 
chronic and continuous stimulation and inﬂ  ammation of 
the biliary tract.
1,2 Polypoid lesions of the gallbladder 
and adenomyomatosis have been regarded as a risk 
factors for gallbladder cancer. In this section, we review 
the respective risk factors for bile duct cancer, gallblad-
der cancer, and ampullary carcinoma.
Table 1.  Strength of recommendations
10
A, Strongly recommend performing the clinical action
B, Recommend performing the clinical action
C1, The clinical action may be considered although there is a 
lack of high-level scientiﬁ  c evidence for its use. May be 
useful
C2, Clinical action not deﬁ  nitively recommended because of 
insufﬁ  cient scientiﬁ  c evidence. Evidence insufﬁ  cient to 
support or deny usefulness
D, Recommend not performing the clinical action
Table 2.  Levels of evidence
10
Level I Systematic review/meta-analysis
Level II One or more randomized clinical trials
Level III Nonrandomized controlled trials
Level IV Analytic epidemiology (cohort studies and case-control studies)
Level V Descriptive study (case reports and case-series studies)
Level VI Opinions of expert panels and individual experts not based on 
patient’s dataM. Miyazaki et al.: Risk factors for biliary cancer and prophylactic surgery   17
Adenomyomatosis (Fig. 3; 4)
Adenomyomatosis has not been considered to have 
malignant potential.
1 Nabatame et al.
9 studied the rela-
tionship between adenomyomatosis and gallbladder 
cancer by examining 4560 gallbladders (2031 from male 
patients and 2529 from female patients; age 14 to 94 
years) resected for gallbladder cancer, gallstones, or 
other diseases. In that study, the incidence of gallbladder 
carcinoma was higher in patients with segmental adeno-
myomatosis (22/334; 6.6%) than in those without 
(181/4226; 4.3%; P = 0.049). This difference was more 
marked in patients equal to or older than 60 years of 
age (P < 0.001). However, the magnitude of risk for 
gallbladder cancer in patients with adenomyomatosis 
has not been clearly established.
1,26
Risk factors for ampullary carcinoma
Kimura et al.
27 histologically investigated the papilla of 
Vater in 576 autopsy cases of elderly people and revealed 
that the incidences of group 3 and 4 epithelia in the 
common channel were signiﬁ  cantly higher than those in 
the intraduodenal portion of the bile duct, pancreatic 
duct, or duodenal epithelia. They also investigated 
Fig.  1.  Macroscopic photograph of adenoma of the 
gallbladder
a b,c
Fig. 2a–c.  Histological examination of adenoma of the gallbladder. a Low magniﬁ  cation; b intermediate magniﬁ  cation; c high 
magniﬁ  cation (H&E)
a family history of gallbladder cancer, and the duration 
of cholelithiasis are potential risk factors for developing 
gallbladder cancer.
1,14–16 However, there is no evidence 
of a direct causal relationship between gallstones and 
gallbladder cancer. Gracie and Ransohoff
17 followed-up 
the subsequent history of 123 patients with asymptom-
atic gallstones for 10 years or longer, and revealed that 
there was no case of gallbladder cancer reported among 
that group.
Controversy remains as to whether patients with 
“porcelain gallbladder” carry a risk of gallbladder 
cancer. It has been reported that porcelain gallbladder 
is often complicated by gallbladder carcinoma
18,19 (level 
IV), while another report suggests that porcelain gall-
bladder is not associated with gallbladder carcinoma
20 
(level IV).
Adenoma of the gallbladder (Figs. 1 and 2; 
also see CQ 4)
There is consensus regarding the existence of two 
models through which malignant transformation is 
produced: the adenoma-carcinoma sequence and the 
dysplasia-carcinoma sequence. Intestinal and gastric 
metaplasias appear to be the pathway through which 
epithelial dysplasia is produced.
21 Yamagiwa
22 examined 
110 cases of resected gallbladder carcinoma and found 
dysplasia adjacent to carcinoma in 46 of the 110 cases, 
and this change was frequently found in lesions at an 
early stage and in well-differentiated carcinoma (level 
V).
Kubota et al.
23 reported that in patients with polypoid 
lesions of the gallbladder, the respective diameters of 
adenomas and cancers were 6.9 mm (range, 4 to 13 mm) 
and 25.7 mm (range, 5 to 50 mm). In that study, 75% of 
the adenomas and 13% of the cancers had a diameter 
of less than 10 mm. It has also been reported that when 
a polypoid lesion of the gallbladder is sessile, has a 
diameter greater than 10 mm, and /or grows rapidly, it is 
highly likely to be cancerous.
23–25 In such cases, surgical 
resection should be recommended.18  M. Miyazaki et al.: Risk factors for biliary cancer and prophylactic surgery 
a
c
b
Fig. 3a–c.  Findings in adenomyomatosis. 
a Fundal type: circumscribed hypertrophy 
of the fundus of the gallbladder with 
Rokitansky-Aschoff sinus. Case com-
plicated by cholecystolithiasis. Upper, 
resected specimen; lower left, abdominal 
computed tomography (CT; cross section); 
lower  right,  abdominal CT (sagittal 
section). b Segmental type: hypertrophy 
circumscribing the gallbladder with 
Rokitansky-Aschoff sinus. Upper, resected 
specimen; lower left, abdominal computed 
tomo  graphy (CT; cross section); lower 
right,  abdominal CT (sagittal section). 
c Diffuse (segmental-diffuse) type: hyper-
trophy and Rokitansky-Aschoff sinus 
from the gallbladder body to the fundus. 
Gallstones in the fundus. Left,  resected 
specimen; right, abdominal CTM. Miyazaki et al.: Risk factors for biliary cancer and prophylactic surgery   19
Fig. 4.  This Loupe image shows growing 
and dilating Rokitansky-Aschoff sinuses 
from the muscularis propria to the subse-
rosa, and the growing smooth muscle 
ﬁ  ber and collagen ﬁ  ber surrounding 
them (H&E)
Side memo 1
Primary sclerosing cholangitis (PSC)
Deﬁ  nition: recurrent or persistent chronic inﬂ  ammatory 
disease of extra- and intrahepatic bile ducts resulting in 
obliterative ﬁ  brosis. No effective treatment has been 
discovered to date, and liver transplant is required in the 
terminal stage. Although autoimmune abnormality is 
suspected, the underlying pathogenesis is still unknown.
Diagnostic criteria
1.  Typical radiological ﬁ  ndings
Typical radiological ﬁ  ndings of bile duct are;
Multifocal stricturing
—   Beaded appearance; short or/and annular strictures 
interspersed among normal or slightly inﬂ  amed ducts. 
This appearance is thought to reﬂ  ect the ﬁ  brous 
stricture portions and the normal segments of the bile 
duct. One-ﬁ  fth of the cases present band-like strictures 
that are extremely short, and one-fourth present 
diverticulum-like outpouchings
—   Pruned-tree appearance; diminished arborization of 
the intrahepatic ducts
—   Shaggy appearance; diffuse mural irregularities of 
extrahepatic bile ducts
2.  Typical clinical presentation
Important clinical history: inﬂ  ammatory bowel disease, 
bile obstruction
Blood examination: high alkaline phosphatase (ALP; 
two or three times upper limit of normal) for 6 months or 
more
3. Deductive  diagnosis
Exclude secondary sclerotic cholangitis as follows:
—  Infectious cholangitis due to AIDS
—   Malignant neoplasms or similar disease in the bile 
duct (excluding PSC accompanied by early-stage 
cholangiocarcinoma)
—    Previous surgery of the biliary tract (excluding 
cholecystectomy)
—    Bacterial cholangitis accompanying biliary tract 
stricturing or biliary calculus
—  Ischemic cholangitis due to ﬂ  oxuridine
Fig.  5.  Endoscopic retrograde cholangiopancreatography 
image of PSC. Multifocal stricturing of intrahepatic and 
extrahepatic bile ducts, and shaggy appearance of extrahe-
patic bile ducts
resected specimens from the patients with carcinoma of 
the papilla of Vater and found tha  the common channel 
was the most frequent site for the possible origin of 
carcinoma (level IV). These results suggest that the 
common channel is the most important site in the patho-
genesis of carcinoma of the papilla of Vater. With regard 
to the incidence of “adenoma” surrounding carcinoma 
of the papilla of Vater, the values have been reported to 
range from 82% to 91%
27  (level IV). Therefore, the 
adenoma-carcinoma sequence is very important in the 
pathogenesis of carcinoma of the papilla of Vater. 
In addition, familial adenomatous polyposis (FAP) is 
notable for the risk of adenoma in the ampulla of 
Vater.20  M. Miyazaki et al.: Risk factors for biliary cancer and prophylactic surgery 
Side memo 2
Diagnostic criteria of pancreaticobiliary maljunction (PBM; 
see Fig 6)
Deﬁ  nition: PBM is a congenital anomaly consisting of a 
union of the pancreatic and bile ducts located outside the 
duodenal wall.
Diagnostic criteria: PBM is diagnosed by either radiological 
or anatomical ﬁ  ndings
1) Radiological  ﬁ  ndings
It is necessary to conﬁ  rm the lack of sphincter action at 
the union of the pancreatic and bile ducts. However, 
because clariﬁ  cation of the lack of sphincter action is 
often difﬁ  cult, the following radiological ﬁ  ndings of endo-
scopic retrograde cholangiopancreatography (ERCP), 
percutaneous transhepatic cholangiography (PTHC), 
intraoperative cholangiography, or similar methods are 
used to verify whether there is a long common channel 
or a complicated conﬂ  uence of the pancreatic and bile 
ducts.
2) Anatomical  ﬁ  ndings
Conﬁ  rm the abnormal anatomical conﬂ  uence of the 
pancreatic and bile ducts outside the duodenal wall or 
conﬁ  rm the complicated conﬂ  uence by surgery, autopsy, 
or other procedures.
a b
Fig. 6a,b.  Endoscopic retrograde cholangiopancreatography 
(ERCP) image of pancreaticobiliary maljunction (PBM): a 
patient with congenital bile duct dilatation (Kotani IV a 
type). a The pancreatic duct joins the biliary duct. b Pancre-
aticobiliary maljunction without bile duct dilatation (Fig 6a, 
with permission from Koyanagi K, Aoki T, editors. Pancreati-
cobiliary maljunction. Tokyo: Igaku Tosho Shuppan: 2002. 
p 25, Fig. 4
29)
CQ 2  Is prophylactic treatment necessary for 
pancreaticobiliary maljunction (PBM)?
PBM with bile duct dilatation is a risk factor for 
bile duct and gallbladder cancer. Prophylactic 
excision of the gallbladder and common bile duct 
should be recommended for PBM with bile duct 
dilatation (recommendation grade C1)
PBM without bile duct dilatation is a risk factor 
for gallbladder cancer. A prophylactic 
cholecystectomy is the appropriate surgical procedure 
for PBM without bile duct dilatation. 
(recommendation grade B)
As mentioned above, a retrospective nationwide 
survey (1990 to 1999) of PBM revealed that the inci-
dence of biliary tract cancer was 10.6% in the group 
with bile duct dilatation; of these biliary tract cancers, 
64.9% were gallbladder carcinoma and 33.6% were bile 
duct cancer.
3 Therefore, PBM with bile duct dilatation 
should be considered as a risk factor for bile duct cancer 
and gallbladder cancer, and in these patients, prophylac-M. Miyazaki et al.: Risk factors for biliary cancer and prophylactic surgery   21
tic excision of the gallbladder and extrahepatic bile duct 
should be considered. Currently, standard prophylactic 
treatment of PBM with bile duct dilatation consists of 
cholecystectomy, extrahepatic biliary duct resection, 
and hepatocholangiojejunostomy.
28
In the PBM patients without bile duct dilatation, the 
incidence of biliary tract cancer was 37.9%, and 93.2% 
of these patients had gallbladder cancer
3  (level IV). 
These reports suggest that PBM without bile duct dila-
tation should be considered as a risk factor for gallblad-
der cancer. Therefore, in these patients, excision of the 
gallbladder should be considered as a minimal prophy-
lactic treatment. Controversy remains as to whether 
prophylactic bile duct resection is necessary in PBM 
patients without bile duct dilatation. It has been reported 
that the long-term results of a prophylactic cholecystec-
tomy without bile duct resection for PBM patients 
without bile duct dilatation were acceptable
29,30 (level 
IV). Also, it has been reported that K-ras gene mutation 
is frequent in the mucosa of the bile duct in PBM 
patients with bile duct dilatation, while no mutation is 
observed in PBM patients without bile duct dilatation
31 
(level IV). These reports support a prophylactic chole-
cystectomy without bile duct resection as being the best 
treatment option for PBM patients without bile duct 
dilatation. In contrast, it has been reported that the 
incidence of bile duct cancer in PBM patients without 
bile duct dilatation is lower than that in PBM patients 
with bile duct dilatation, but the incidence seems higher 
than that in healthy controls
3,32 (level IV). Moreover, it 
has been reported that K-ras and p53 gene mutations 
are found frequently even in the nondilated bile duct in 
patients with PBM
33 (level IV). These reports support 
the possibility that complete excision of the common 
bile duct may be needed to decrease the risk of bile duct 
cancer.
tionship between gallstones and gallbladder cancer. 
Maringhini et al.
34 followed-up, for more than 31  000 
person-years a total of 2583 residents of Rochester, 
Minnesota, who had gallstones. Gallbladder cancer 
developed in 5 patients after a median follow-up of 13.3 
years. The incidence of gallbladder cancer was signiﬁ  -
cantly higher than expected for men but not for women 
(153 vs 18 per 100  000 person-years). However, these 
authors do not recommend cholecystectomy, because 
the absolute incidence and the total numbers of men 
and women who developed gallbladder cancer were 
low. Moreover, Gracie and Ransohoff
17 followed up the 
subsequent history of 123 patients with asymptomatic 
gallstones for 10 years or longer, and revealed that there 
was no case of gallbladder cancer reported among that 
group. This low rate of cancer development in asymp-
tomatic patients with gallstones is similar to that noted 
in other reports (0.01%/year-0.02%/year)
1,35  and, in 
general, this low rate has lent support to the practice of 
not performing prophylactic cholecystectomy in patients 
with asymptomatic cholelithiasis.
Controversy remains as to whether patients with cal-
ciﬁ  cation of the wall of the gallbladder, referred to as 
“porcelain gallbladder” carry a risk of gallbladder 
cancer. It has been reported that porcelain gallbladder 
is often complicated by gallbladder carcinoma
18,19 (level 
IV). However, Towﬁ  gh et al.
20 have reported that por-
celain gallbladder is not associated with gallbladder car-
cinoma (level IV). The pathogenic mechanism underlying 
the relationship of calciﬁ  cation to gallbladder cancer 
also remains unknown.
CQ 3 Is a cholecystectomy required for asymptom-
atic cholecystolithiasis?
A cholecystectomy is not advised for asymptomatic 
cholecystolithiasis (recommendation grade C2)
It has been well established that gallstones are associ-
ated with gallbladder cancer
1,8  (level V). Not only is 
there an increased prevalence of gallbladder cancer in 
patients with gallstones but up to 75% of patients with 
gallbladder cancer have been noted to have had gall-
stones.
1 It has also been reported that a stone size of 
more than 3 cm, a family history of gallbladder cancer, 
and the duration of cholelithiasis are potential risk 
factors for the development of gallbladder cancer.
1,14–16 
However, there is no evidence of a direct causal rela-
CQ 4 Is a cholecystectomy necessary for polypoid 
lesions of the gallbladder (see side memo 3)
When a polypoid lesion of the gallbladder is sessile, 
has a diameter greater than 10  mm, and/or grows 
rapidly, it is highly likely to be cancerous and 
should be resected (recommendation grade B)
Currently, adenoma and dysplasia have been regarded 
as a precancerous lesions of the gallbladder.
21 Intestinal 
and gastric metaplasia seems to be the pathway 
through which the epithelial dysplasia is produced.
21,22 
Yamagiwa
22 examined 110 cases of resected gallbladder 
carcinoma and revealed that dysplasia adjacent to 
carcinoma was found in 46 of the 110 cases, and this 
change was frequently found in lesions at the early 
stage and in well-differentiated carcinoma (level V).
Kubota et al.
23 evaluated 72 patients who underwent 
cholecystectomy for polypoid lesions of the gallbladder. 
In that study, histological examination showed choles-
terol polyps in 47 patients, adenoma in 8, cancers in 16, 22  M. Miyazaki et al.: Risk factors for biliary cancer and prophylactic surgery 
and an inﬂ  ammatory polyp in 1. The respective diame-
ters of the adenomas and cancers were 6.9  mm (range, 
4 to 13  mm) and 25.7  mm (range, 5 to 50  mm); 75% of 
the adenomas and 13% of the cancers had a diameter 
of less than 10 mm (level IV). Chijiiwa and Tanaka
36 also 
examined 44 patients who underwent cholecystectomy 
for polypoid lesions of the gallbladder, and reported 
that the sex ratio, symptoms, and the presence of gall-
stones were not signiﬁ  cantly different between patients 
with carcinoma and those with benign polypoid lesions, 
and that the size (>10 mm), number of polypoid lesions 
(single), and age (> or =60 years) were signiﬁ  cant indica-
tors of carcinoma.
It has been reported that when a polypoid lesion of 
the gallbladder is sessile, has a diameter greater than 
10  mm, and/or grows rapidly, it is highly likely to be 
cancerous
23–25,36–39  (level IV). In such cases, surgical 
resection should be considered.
Side memo 3
Polypoid lesions of the gallbladder (see Figs. 7–10)
Deﬁ  nition: “Polypoid” is the general term for torous lesions 
protruding into the lumen of the gallbladder, no matter 
whether they are neoplastic or nonneoplastic. The majority 
of polypoid lesions are nonneoplastic lesions such as 
cholesterol polyp, adenomyomatosis, or inﬂ  ammatory polyp. 
Benign neoplastic lesions include adenoma and metaplastic 
polyp, while malignant neoplastic lesions include gallbladder 
cancer
Fig. 7.  Ultrasound image of a cholesterol polyp: sessile polyp 
that has a higher echoic signal than the liver
Fig. 8.  Ultrasound image of adenoma of the gallbladder: this 
image indicates a semipedunculate polyp with isoechoic 
signal
Fig.  9.  Ultrasound image of early-stage gallbladder carci-
noma: a pedunculated protrusion with a relatively high echoic 
signal. Depth of tumor invasion is limited to the mucosal 
layer
Fig. 10.  Ultrasound image of gallbladder carcinoma: sessile 
protruding lesion. Depth of tumor invasion is to the 
subserosaM. Miyazaki et al.: Risk factors for biliary cancer and prophylactic surgery   23
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